Alzheimer lesions in the autopsied brains of people 30 to 50 years of age

Cognitive and Behavioral Neurology

Volumn 28, Issue 3, 2015, Pages 144-152

  Pletnikova, Olga ^a   Rudow, Gay L ^a   Hyde, Thomas M ^b   Kleinman, Joel E ^b   Ali, Sabeen Z ^a   Bharadwaj, Rahul ^a,b   Gangadeen, Salina ^a   Crain, Barbara J ^a   Fowler, David R ^c   Rubio, Ana I ^c   Troncoso, Juan C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LIEBER INSTITUTE FOR BRAIN DEVELOPMENT   (United States)

^c OFFICE OF THE CHIEF MEDICAL EXAMINER   (United States)

Author keywords

Amyloid b; APOE; Asymptomatic Alzheimer disease; Preclinical Alzheimer disease

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; DNA; TAU PROTEIN;

ACCIDENT; ADULT; AFRICAN AMERICAN; AGE; ALZHEIMER DISEASE; AMYLOID PLAQUE; APOE GENE; ARTERIOSCLEROSIS; ARTICLE; AUTOPSY; BRAIN; BRAIN CORTEX; CAUCASIAN; CAUSE OF DEATH; DROWNING; ENTORHINAL CORTEX; FEMALE; FRONTAL CORTEX; GENE; GENOTYPE; GUNSHOT INJURY; HEART ARRHYTHMIA; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; INFERIOR PARIETAL LOBULE; INTOXICATION; MAJOR CLINICAL STUDY; MALE; MEGACOLON; MICROSCOPY; MIDDLE TEMPORAL GYRUS; MULTIPLE TRAUMA; NEOCORTEX; NEURITE; NEUROFIBRILLARY TANGLE; PRIORITY JOURNAL; RACE; SUICIDE; SUPERIOR TEMPORAL GYRUS; TEMPORAL GYRUS; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADULT; ALZHEIMER DISEASE; AUTOPSY; BRAIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROFIBRILLARY TANGLES; PLAQUE, AMYLOID;

EID: 84942783496     PISSN: 15433633     EISSN: 15370887     Source Type: Journal    
DOI: 10.1097/WNN.0000000000000071     Document Type: Article

References (53)

1. Aizenstein HJ, Nebes RD, Saxton JA, et al. 2008. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 65: 1509-1517.
2. Bateman RJ, Xiong C, Benzinger TL, et al. 2012. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 367: 795-804.
3. Bennett DA, Schneider JA, Arvanitakis Z, et al. 2006. Neuropathology of older persons without cognitive impairment from two communitybased studies. Neurology. 66: 1837-1844.
4. Braak H, Thal DR, Ghebremedhin E, et al. 2011. Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years. J Neuropathol Exp Neurol. 70: 960-969.
5. Burger PC, Vogel FS. 1973. The development of the pathologic changes of Alzheimer's disease and senile dementia in patients with Down's syndrome. Am J Pathol. 73: 457-476.
6. Corder EH, Saunders AM, Strittmatter WJ, et al. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261: 921-923.
7. Cork LC. 1990. Neuropathology of Down syndrome and Alzheimer disease. Am J Med Genet Suppl. 7: 282-286.
8. Crystal H, Dickson D, Fuld P, et al. 1988. Clinico-pathologic studies in dementia: Nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology. 38: 1682-1687.
9. Davis DG, Schmitt FA, Wekstein DR, et al. 1999. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol. 58: 376-388.
10. Dickson DW, Crystal HA, Mattiace LA, et al. 1992. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging. 13: 179-189.
11. Driscoll I, Resnick SM, Troncoso JC, et al. 2006. Impact of Alzheimer's pathology on cognitive trajectories in nondemented elderly. Ann Neurol. 60: 688-695.
12. Driscoll I, Troncoso J. 2011. Asymptomatic Alzheimer's disease: A prodrome or a state of resilience? Curr Alzheimer Res. 8: 330-335.
13. Fagan AM, Xiong C, Jasielec MS, et al. 2014. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med. 6: 226-230.
14. Fortea J, Vilaplana E, Alcolea D, et al. 2014. Cerebrospinal fluid betaamyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. Ann Neurol. 76: 223-230.
15. Guerreiro R, Bras J, Hardy J. 2013. SnapShot: Genetics of Alzheimer's disease. Cell. 155: 968-968 e961.
16. Guerreiro RJ, Gustafson DR, Hardy J. 2012. The genetic architecture of Alzheimer's disease: Beyond APP, PSENs and APOE. Neurobiol Aging. 33: 437-456.
17. Gustafson DR, Skoog I, Rosengren L, et al. 2007. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry. 78: 461-464.
18. Hardy J. 2009. The amyloid hypothesis for Alzheimer's disease: A critical reappraisal. J Neurochem. 110: 1129-1134.
19. Hardy JA, Higgins GA. 1992. Alzheimer's disease: The amyloid cascade hypothesis. Science. 256: 184-185.
20. Hixson JE, Vernier DT. 1990. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 31: 545-548.
21. Hulette CM, Welsh-Bohmer KA, Murray MG, et al. 1998. Neuropathological and neuropsychological changes in "normal" aging: Evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 57: 1168-1174.
22. Jack CR Jr, Knopman DS, Jagust WJ, et al. 2013. Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12: 207-216.
23. Katzman R, Terry R, DeTeresa R, et al. 1988. Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol. 23: 138-144.
24. Klunk WE, Engler H, Nordberg A, et al. 2004. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 55: 306-319.
25. Knopman DS, Parisi JE, Salviati A, et al. 2003. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 62: 1087-1095.
26. Li G, Sokal I, Quinn JF, et al. 2007. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: A follow-up study. Neurology. 69: 631-639.
27. Mann DM, Esiri MM. 1989. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci. 89: 169-179.
28. Miller FD, Hicks SP, D'Amato CJ, et al. 1984. A descriptive study of neuritic plaques and neurofibrillary tangles in an autopsy population. Am J Epidemiol. 120: 331-341.
29. Mintun MA, Larossa GN, Sheline YI, et al. 2006. [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology. 67: 446-452.
30. Morris JC, Price JL. 2001. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci. 17: 101-118.
31. Morris JC, Roe CM, Xiong C, et al. 2010. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 67: 122-131.
32. Morris JC, Storandt M, Miller JP, et al. 2001. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 58: 397-405.
33. Price JL, McKeel DW Jr, Buckles VD, et al. 2009. Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 30: 1026-1036.
34. Price JL, Morris JC. 1999. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 45: 358-368.
35. Reiman EM, Caselli RJ, Yun LS, et al. 1996. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 334: 752-758.
36. Reiman EM, Chen K, Liu X, et al. 2009. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA. 106: 6820-6825.
37. Resnick SM, Sojkova J, Zhou Y, et al. 2010. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology. 74: 807-815.
38. Riudavets MA, Rubio A, Cox C, et al. 2006. The prevalence of Alzheimer neuropathologic lesions is similar in blacks and whites. J Neuropathol Exp Neurol. 65: 1143-1148.
39. Rogaeva E. 2002. The solved and unsolved mysteries of the genetics of early-onset Alzheimer's disease. Neuromolecular Med. 2: 1-10.
40. Sandberg G, Stewart W, Smialek J, et al. 2001. The prevalence of the neuropathological lesions of Alzheimer's disease is independent of race and gender. Neurobiol Aging. 22: 169-175.
41. Schmitt FA, Davis DG, Wekstein DR, et al. 2000. "Preclinical" AD revisited: Neuropathology of cognitively normal older adults. Neurology. 55: 370-376.
42. Selkoe DJ. 1991. The molecular pathology of Alzheimer's disease. Neuron. 6: 487-498.
43. Seppala TT, Koivisto AM, Hartikainen P, et al. 2011. Longitudinal changes of CSF biomarkers in Alzheimer's disease. J Alzheimers Dis. 25: 583-594.
44. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. 2009. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 65: 403-413.
45. Sparks DL, Liu H, Scheff SW, et al. 1993. Temporal sequence of plaque formation in the cerebral cortex of non-demented individuals. J Neuropathol Exp Neurol. 52: 135-142.
46. Sperling RA, Jack CR Jr, Black SE, et al. 2011. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 7: 367-385.
47. Tomlinson BE, Blessed G, Roth M. 1968. Observations on the brains of non-demented old people. J Neurol Sci. 7: 331-356.
48. Troncoso JC, Cataldo AM, Nixon RA, et al. 1998. Neuropathology of preclinical and clinical late-onset Alzheimer's disease. Ann Neurol. 43: 673-676.
49. Troncoso JC, Martin LJ, Dal Forno G, et al. 1996. Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. Neurobiol Aging. 17: 365-371.
50. Verghese PB, Castellano JM, Holtzman DM. 2011. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol. 10: 241-252.
51. Villemagne VL, Pike KE, Darby D, et al. 2008. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia. 46: 1688-1697.
52. Wirth M, Villeneuve S, La Joie R, et al. 2014. Gene-environment interactions: Lifetime cognitive activity, APOE genotype, and betaamyloid burden. J Neurosci. 34: 8612-8617.
53. Yamamoto T, Hirano A. 1986. A comparative study of modified Bielschowsky, Bodian and thioflavin S stains on Alzheimer's neurofibrillary tangles. Neuropathol Appl Neurobiol. 12: 3-9.